ArticleACS applied bio materials2025
Combination Diagnostics In Vivo: Dual-Mode Ultrasound/NIR Fluorescence Imaging with Neodymium- and Thulium-Doped Graphene Quantum Dots.
Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The combination of two biomedical imaging techniques, fluorescence and ultrasound imaging, can uniquely offer enhanced anatomical visualization, sensitivity, and specificity necessary for improved diagnostic accuracy in detecting small tumors, tracing therapeutic delivery, and guiding biopsies. This work aims to harness the advantages of highly deterministic fluorescence imaging and deeply penetrating ultrasound diagnostics in neodymium- and thulium-doped graphene quantum dot (Nd-NGQD and Tm-NGQD) ultrasound/near-infrared (NIR) fluorescence contrast agents. These biocompatible nanostructures are tested for dual-mode fluorescence/ultrasound imaging in vivo in live sedated BALB/c mice as well as in animal organs. Injected intravenously (IV), Tm-NGQDs and Nd-NGQDs exhibit ultrasound enhancement and NIR fluorescence in the liver, spleen, and kidneys. The best agreement is achieved between the two techniques in the liver at 12 h for Tm-NGQDs and in the liver at 24 h, in the spleen at 6 h, and in the kidneys at 12 h for Nd-NGQDs, suggesting the optimal timeline for imaging. IP-injected Nd-NGQDs demonstrate a greater consistency between ultrasound enhancement and NIR fluorescence within 1-48 h time points in all imaged organs. Metal-doped GQD contrast agents developed for the first time in this work hold significant promise for dual-mode ultrasound-fluorescence imaging, paving the way for improved diagnostics and therapeutic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.